Evidence map›Paper›PMID 30614649›Full record

Trial reportAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2019

Steroid pretreatment of organ donors does not impact on early rejection and long-term kidney allograft survival: Results from a multicenter randomized, controlled trial.

Roman Reindl-Schwaighofer, Alexander Kainz, Kira Jelencsics, Andreas Heinzel, Gabriela Berlakovich, Ádám Remport, Georg Heinze, Robert Langer, Rainer Oberbauer

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Steroid pretreatment of organ donors does not impact on early rejection and long-term kidney allograft survival: Results from a multicenter randomized, controlled trial.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019
    Trial
  2. Observational
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Roman Reindl-SchwaighoferDepartment of Nephrology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-4419-6282
Alexander KainzDepartment of Nephrology, Medical University of Vienna, Vienna, Austria.
Kira JelencsicsDepartment of Nephrology, Medical University of Vienna, Vienna, Austria.
Andreas HeinzelDepartment of Nephrology, Medical University of Vienna, Vienna, Austria.
Gabriela BerlakovichDepartment of Surgery, Medical University of Vienna, Vienna, Austria.
Ádám RemportDepartment of Nephrology, Semmelweis University, Budapest, Hungary.
Georg HeinzeCenter for Medical Statistics, Informatics and Intelligent Systems (CEMSIIS), Medical University of Vienna, Vienna, Austria.
Robert LangerDepartment of Surgery, Elisabethinen Krankenhaus, Linz, Austria.
Rainer OberbauerDepartment of Nephrology, Medical University of Vienna, Vienna, Austria.

Funding

Austrian Science Fund FWF P-18325SandozVienna Science and Technology Fund LS16-019
6 · The paper itself

Abstract

Steroid pretreatment of deceased donors reduces inflammation in allografts and is recommended by organ procurement guidelines. The impact on long-term graft outcome, however, remains elusive. In this multicenter randomized controlled trial, 306 deceased donors providing organs for 455 renal transplant recipients were randomized to 1000 mg of methylprednisolone or placebo prior to organ procurement (ISRCTN78828338). The incidence of biopsy-confirmed rejection (Banff>1) at 3 months was 23 (10%) in the steroid group and 26 (12%) in the placebo group (P = .468). Five-year functional graft survival was 84% and 82% for the steroid group and placebo group, respectively (P-value = .941). The hazard ratio of functional graft loss was 0.90 (95% confidence interval 0.57-1.42, P = .638) for steroid vs placebo in a multivariate Cox model. We did not observe effect modification by any of the predictors of graft survival and treatment modality. A robust sandwich estimate was used to account for paired grafts of some donors. The mean estimated GFR at 5 years was 47 mL/min per 1.73 m

Indexed as

Graft SurvivalKidney TransplantationAdultBiopsyFemaleGlomerular Filtration RateGraft RejectionHumansIncidenceInflammationMaleMethylprednisoloneMiddle AgedMultivariate AnalysisProportional Hazards ModelsSteroidsMethylprednisoloneSteroidsclinical trialcritical care/intensive care managementdonors and donation: deceasedgraft survivalkidney transplantation/nephrologyorgan procurement and allocationtranslational research/science

Identifiers

PMID30614649
PMCPMC6563104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.